

Victoria P Werth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8631746/publications.pdf>

Version: 2024-02-01

327
papers

18,986
citations

20759

60
h-index

15683

125
g-index

383
all docs

383
docs citations

383
times ranked

13004
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1955-1964.	0.5	754
3	Anifrolumab, an Anti-Interferon- γ Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 376-386.	2.9	634
4	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1043-1046.	0.6	464
5	Sifalimumab, an anti-interferon- γ monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1909-1916.	0.5	420
6	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017, 69, 2271-2282.	2.9	391
7	The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2005, 125, 889-894.	0.3	376
8	Update on morphea. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 217-228.	0.6	335
9	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1269-1274.	0.5	308
10	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (CHAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. <i>Arthritis Care and Research</i> , 2011, 63, S118-57.	1.5	288
11	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
12	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet</i> , The, 2018, 392, 1330-1339.	6.3	244
13	Cutaneous lupus erythematosus: Diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 391-404.	1.4	227
14	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 575-585.e1.	0.6	224
15	Classification of myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 269-278.	3.5	210
16	Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2404-2410.	0.3	183
17	Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2019, 129, 1359-1371.	3.9	177
18	Update on morphea. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 231-242.	0.6	161

#	ARTICLE	IF	CITATIONS
19	International consensus for a definition of disease flare in lupus. <i>Lupus</i> , 2011, 20, 453-462.	0.8	152
20	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92.	0.3	148
21	Quality of life in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 849-858.	0.6	145
22	Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus. <i>Archives of Dermatology</i> , 2011, 147, 203.	1.7	138
23	Clinical manifestations of cutaneous lupus erythematosus. <i>Autoimmunity Reviews</i> , 2005, 4, 296-302.	2.5	137
24	Cutaneous lupus erythematosus: a review. <i>Dermatologic Clinics</i> , 2002, 20, 373-385.	1.0	136
25	Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 168-174.	0.6	133
26	TNF- α production in the skin. <i>Archives of Dermatological Research</i> , 2009, 301, 87-91.	1.1	130
27	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1-9.	0.6	126
28	Mycophenolate mofetil for interstitial lung disease in dermatomyositis. <i>Arthritis Care and Research</i> , 2010, 62, 1496-1501.	1.5	125
29	Response to Antimalarial Agents in Cutaneous Lupus Erythematosus. <i>Archives of Dermatology</i> , 2011, 147, 1261.	1.7	123
30	The interferon- α regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. <i>British Journal of Dermatology</i> , 2012, 166, 971-975.	1.4	123
31	A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 903-908.	0.6	120
32	Association of a Promoter Polymorphism of Tumor Necrosis Factor- α with Subacute Cutaneous Lupus Erythematosus and Distinct Photoregulation of Transcription1,21Werth VP, Sullivan K: Strong association of a promoter polymorphism of tumor necrosis factors α with a photosensitive form of cutaneous lupus erythematosus. <i>Arthr Rheum</i> 42:S105 1999 (abstr.)2Werth VP, Zhang W, Sullivan K: Role of a promoter polymorphism of tumor necrosis factor- α (TNF- α) in a photosensitive form of lupus erythematosus (LE): clinical a. <i>Journal of Investigative Dermatology</i> , 2000, 115, 726-730.	0.3	117
33	Adjuvant Rituximab Therapy of Pemphigus. <i>Archives of Dermatology</i> , 2012, 148, 1031-6.	1.7	115
34	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 201-207.	0.6	115
35	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017, 3, e000507.	1.8	115
36	UVB and Proinflammatory Cytokines Synergistically Activate TNF- α Production in Keratinocytes through Enhanced Gene Transcription. <i>Journal of Investigative Dermatology</i> , 2009, 129, 994-1001.	0.3	107

#	ARTICLE	IF	CITATIONS
37	Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 839-849.	0.8	103
38	Pathophysiology of Cutaneous Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 33, 85-106.	2.9	102
39	Interventions for pemphigus vulgaris and pemphigus foliaceus. <i>The Cochrane Library</i> , 2009, , CD006263.	1.5	100
40	Deletion of Decay-Accelerating Factor (CD55) Exacerbates Autoimmune Disease Development in MRL/lpr Mice. <i>American Journal of Pathology</i> , 2002, 161, 1077-1086.	1.9	97
41	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
42	Impact of Smoking in Cutaneous Lupus Erythematosus. <i>Archives of Dermatology</i> , 2012, 148, 317.	1.7	89
43	Pathophysiology of cutaneous lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 182.	1.6	88
44	Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris. <i>Archives of Dermatology</i> , 2008, 144, 25-32.	1.7	87
45	Systemic Symptoms in the Progression of Cutaneous to Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2014, 150, 291.	2.0	87
46	The Cutaneous Lupus Erythematosus Disease Area and Severity Index. <i>Archives of Dermatology</i> , 2008, 144, 173-80.	1.7	86
47	Quality of life in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1107-1116.	0.6	86
48	Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis. <i>JAMA Dermatology</i> , 2015, 151, 952.	2.0	85
49	Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. <i>British Journal of Dermatology</i> , 2008, 159, 887-894.	1.4	82
50	Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 135-146.	3.3	81
51	Combination Antimalarials in the Treatment of Cutaneous Dermatomyositis. <i>Archives of Dermatology</i> , 2005, 141, 855-9.	1.7	78
52	Associations of Tumor Necrosis Factor $\hat{\pm}$ and HLA Polymorphisms with Adult Dermatomyositis: Implications for a Unique Pathogenesis1. <i>Journal of Investigative Dermatology</i> , 2002, 119, 617-620.	0.3	77
53	Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. <i>British Journal of Dermatology</i> , 2015, 173, 969-974.	1.4	76
54	Tumid lupus erythematosus: Criteria for classification with immunohistochemical analysis. <i>Arthritis and Rheumatism</i> , 2003, 49, 494-500.	6.7	73

#	ARTICLE	IF	CITATIONS
55	Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. <i>Autoimmunity Reviews</i> , 2011, 10, 383-388.	2.5	71
56	The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. <i>Cytokine</i> , 2015, 73, 326-334.	1.4	69
57	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	0.9	69
58	Treatment of Cutaneous Lupus. <i>Current Rheumatology Reports</i> , 2011, 13, 300-307.	2.1	68
59	Calculation of cutaneous values based on the Autoimmune Bullous Skin Disorder Intensity Score () Tj ETQq1 1 0.784314 rgBT /Overlock for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , 2016, 175, 142-149.	1.4	68
60	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 11-16.	0.6	68
61	Itch in dermatomyositis: the role of increased skin interleukin-31. <i>British Journal of Dermatology</i> , 2018, 179, 669-678.	1.4	66
62	Incidence of alopecia areata in lupus erythematosus. <i>Archives of Dermatology</i> , 1992, 128, 368-371.	1.7	66
63	Resistant discoid lupus erythematosus of palms and soles: Successful treatment with azathioprine. <i>Journal of the American Academy of Dermatology</i> , 1988, 19, 961-965.	0.6	63
64	Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-3 Antibody, in Patients With Discoid Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1028-1034.	2.9	62
65	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	1.1	62
66	Pemphigus. <i>Dental Clinics of North America</i> , 2013, 57, 597-610.	0.8	58
67	Small Vessel Vasculitis of the Skin. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 21-32.	0.8	58
68	Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. <i>New England Journal of Medicine</i> , 2021, 384, 2295-2305.	13.9	58
69	The cutaneous lupus erythematosus disease activity and severity index: Expansion for rheumatology and dermatology. <i>Arthritis and Rheumatism</i> , 2008, 59, 338-344.	6.7	57
70	American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. <i>Arthritis and Rheumatology</i> , 2021, 73, 908-911.	2.9	57
71	Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. <i>British Journal of Dermatology</i> , 2010, 162, 669-673.	1.4	56
72	Interstitial Lung Disease in Classic and Skin-Predominant Dermatomyositis. <i>Archives of Dermatology</i> , 2010, 146, 729-38.	1.7	55

#	ARTICLE	IF	CITATIONS
73	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.3	55
74	Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus-Associated Skin Lesions. <i>Archives of Dermatology</i> , 2009, 145, 255-60.	1.7	54
75	Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, S11-S14.	0.6	53
76	Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , 2007, 20, 93-101.	0.8	53
77	Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 571-582.	0.6	53
78	The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent. <i>Scientific Reports</i> , 2020, 10, 7908.	1.6	53
79	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 191-198.	0.6	52
80	Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 937-943.	0.6	51
81	Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000284.	1.1	51
82	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	51
83	A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2013, 168, 145-153.	1.4	50
84	Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	50
85	Lenalidomide for the Treatment of Resistant Discoid Lupus Erythematosus. <i>Archives of Dermatology</i> , 2009, 145, 303-6.	1.7	49
86	The impact of skin damage due to cutaneous lupus on quality of life. <i>British Journal of Dermatology</i> , 2014, 170, 315-321.	1.4	48
87	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 261-267.	0.6	48
88	Characterization of clinical photosensitivity in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 205-213.	0.6	47
89	Grading criteria for disease severity by pemphigus disease area index. <i>Journal of Dermatology</i> , 2014, 41, 969-973.	0.6	47
90	A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. <i>British Journal of Dermatology</i> , 2015, 172, 760-768.	1.4	47

#	ARTICLE	IF	CITATIONS
91	Cutaneous lupus: insights into pathogenesis and disease classification. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65, 200-4.	0.7	47
92	Mannose Binding Lectin (MBL) Polymorphisms Associated with Low MBL Production in Patients with Dermatomyositis ¹ . Journal of Investigative Dermatology, 2002, 119, 1394-1399.	0.3	46
93	Translocation of Endogenous Danger Signal HMGB1 From Nucleus to Membrane Microvesicles in Macrophages. Journal of Cellular Physiology, 2016, 231, 2319-2326.	2.0	46
94	Microvesicles in Autoimmune Diseases. Advances in Clinical Chemistry, 2016, 77, 125-175.	1.8	46
95	Prevalence of self-report photosensitivity in cutaneous lupus erythematosus. Journal of the American Academy of Dermatology, 2012, 66, 220-228.	0.6	45
96	Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. Journal of the American Academy of Dermatology, 2018, 78, 100-106.e1.	0.6	44
97	Systemic sclerosis: Current concepts of skin and systemic manifestations. Clinics in Dermatology, 2018, 36, 459-474.	0.8	43
98	Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. Journal of the American Academy of Dermatology, 2018, 79, 77-83.e1.	0.6	42
99	Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. JAMA Dermatology, 2019, 155, 1404.	2.0	42
100	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*. British Journal of Dermatology, 2021, 185, 745-755.	1.4	42
101	Management of Cutaneous Dermatomyositis. American Journal of Clinical Dermatology, 2006, 7, 341-351.	3.3	41
102	Evaluation of Reliability, Validity, and Responsiveness of the CDASI and the CAT-BM. Journal of Investigative Dermatology, 2012, 132, 1117-1124.	0.3	41
103	Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatologic Therapy, 2013, 26, 354-363.	0.8	41
104	Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. Journal of the American Academy of Dermatology, 2014, 70, 583-584.	0.6	41
105	Alopecias in lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000291.	1.1	41
106	Stroke and Deep Venous Thrombosis Complicating Intravenous Immunoglobulin Infusions. Archives of Dermatology, 2003, 139, 991.	1.7	40
107	Animal Models of Acute Photodamage: Comparisons of Anatomic, Cellular and Molecular Responses in C57BL/6J, SKH1 and Balb/c Mice. Photochemistry and Photobiology, 2011, 87, 690-698.	1.3	40
108	Reliability and Convergent Validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for Assessing Cutaneous Sarcoidosis. JAMA Dermatology, 2013, 149, 550.	2.0	40

#	ARTICLE	IF	CITATIONS
109	Rituximab in the Treatment of Bullous Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 142-144.	0.5	39
110	Dermatomyositis. , 2008, 10, 313-332.		38
111	Nuclear envelope rupture and NET formation is driven by PKC δ -mediated lamin B disassembly. <i>EMBO Reports</i> , 2020, 21, e48779.	2.0	38
112	The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus. <i>Autoimmunity Reviews</i> , 2009, 8, 320-324.	2.5	37
113	Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE). <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 862-869.	0.6	36
114	Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 1997, 9, 400-409.	2.0	35
115	Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris. <i>Archives of Dermatology</i> , 2005, 141, 699-702.	1.7	35
116	Analysis of Compact Fluorescent Lights for Use by Patients with Photosensitive Conditions. <i>Photochemistry and Photobiology</i> , 2009, 85, 1004-1010.	1.3	35
117	Quality of life in patients with bullous dermatoses. <i>Clinics in Dermatology</i> , 2012, 30, 103-107.	0.8	35
118	The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. <i>International Journal of Women's Dermatology</i> , 2017, 3, 189-194.	1.1	34
119	Cutaneous Lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Instrument. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 33-51.	0.8	33
120	Quinacrine Suppresses Tumor Necrosis Factor- α and IFN- α in Dermatomyositis and Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S57-S63.	0.8	33
121	Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor- α , and Type I Interferons in Dermatomyositis In Vitro. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2445-2447.	0.3	33
122	Increased Myeloid Dendritic Cells and TNF- α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2019, 139, 324-332.	0.3	33
123	Elastic Fiber-Associated Proteins of Skin in Development and Photoaging. <i>Photochemistry and Photobiology</i> , 1996, 63, 308-313.	1.3	32
124	Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: A review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual. <i>International Journal of Dermatology</i> , 2004, 43, 87-94.	0.5	32
125	Photosensitivity in Rheumatic Diseases. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2004, 9, 57-63.	0.8	32
126	Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. <i>Arthritis Research and Therapy</i> , 2012, 14, R1.	1.6	32

#	ARTICLE	IF	CITATIONS
127	Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. <i>British Journal of Dermatology</i> , 2015, 172, 169-174.	1.4	32
128	A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 377-379.	0.6	32
129	Update on management of connective tissue panniculitides. <i>Dermatologic Therapy</i> , 2012, 25, 173-182.	0.8	31
130	UVB Irradiation Alters Cellular Responses to Cytokines: Role in Extracellular Matrix Gene Expression. <i>Journal of Investigative Dermatology</i> , 1997, 108, 290-294.	0.3	30
131	IL-12 Completely Blocks Ultraviolet-Induced Secretion of Tumor Necrosis Factor α from Cultured Skin Fibroblasts and Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2003, 120, 116-122.	0.3	30
132	Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFN α Production From Patients Affected With Cutaneous Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 275.	2.2	30
133	The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria. <i>British Journal of Dermatology</i> , 2019, 180, 1001-1008.	1.4	30
134	The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 128-34.	0.4	30
135	Dapsone in the Management of Autoimmune Bullous Diseases. <i>Dermatologic Clinics</i> , 2011, 29, 561-564.	1.0	29
136	Ultraviolet Irradiation Induces the Accumulation of Chondroitin Sulfate, but Not Other Glycosaminoglycans, in Human Skin. <i>PLoS ONE</i> , 2011, 6, e14830.	1.1	29
137	Biological therapies in the treatment of cutaneous lupus erythematosus. <i>Lupus</i> , 2017, 26, 115-118.	0.8	28
138	Squamous Cell Carcinomas Arising in Discoid Lupus Erythematosus Scars. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 35-36.	0.5	27
139	Cigarette Smoking and Response to Antimalarials in Cutaneous Lupus Erythematosus Patients: Evolution of a Dogma. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1968-1970.	0.3	27
140	Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. <i>Quality of Life Research</i> , 2015, 24, 2257-2260.	1.5	27
141	Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. <i>Clinics in Dermatology</i> , 2016, 34, 344-352.	0.8	27
142	Treatment of Autoimmune Bullous Disorders in Pregnancy. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 391-403.	3.3	27
143	Dermatomyositis: A diagnostic dilemma. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 371-373.	0.6	27
144	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , 2018, 5, 306.	1.2	27

#	ARTICLE	IF	CITATIONS
145	Thalidomide in Cutaneous Lupus Erythematosus. American Journal of Clinical Dermatology, 2003, 4, 379-387.	3.3	26
146	Quality of Life Differences Between Responders and Nonresponders in the Treatment of Cutaneous Lupus Erythematosus. JAMA Dermatology, 2013, 149, 104.	2.0	26
147	Identification and Molecular Analysis of Glycosaminoglycans in Cutaneous Lupus Erythematosus and Dermatomyositis. Journal of Histochemistry and Cytochemistry, 2011, 59, 336-345.	1.3	25
148	Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. Journal of Investigative Dermatology, 2016, 136, 1990-2002.	0.3	25
149	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. British Journal of Dermatology, 2020, 182, 410-417.	1.4	25
150	Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology, 2022, 61, 2413-2423.	0.9	25
151	Gottron's Papules Exhibit Dermal Accumulation of CD44 Variant 7 (CD44v7) and Its Binding Partner Osteopontin: A Unique Molecular Signature. Journal of Investigative Dermatology, 2012, 132, 1825-1832.	0.3	24
152	Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis. Journal of the American Academy of Dermatology, 2018, 78, 769-775.e2.	0.6	24
153	Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. Journal of Investigative Dermatology, 2021, 141, 2858-2865.e4.	0.3	24
154	Wavelength-Specific Synergy Between Ultraviolet Radiation and Interleukin-1 β in the Regulation of Matrix-Related Genes: Mechanistic Role for Tumor Necrosis Factor- α . Journal of Investigative Dermatology, 1999, 113, 196-201.	0.3	23
155	Clinical outcome measures for cutaneous lupus erythematosus. Lupus, 2010, 19, 1137-1143.	0.8	23
156	Cutaneous lupus erythematosus induced by drugs - novel insights. Expert Review of Clinical Pharmacology, 2020, 13, 35-42.	1.3	23
157	Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. British Journal of Dermatology, 2017, 177, 1086-1092.	1.4	22
158	Environmental triggers of dermatomyositis: a narrative review. Annals of Translational Medicine, 2021, 9, 434-434.	0.7	22
159	Highly Multiplexed Mass Cytometry Identifies the Immunophenotype in the Skin of Dermatomyositis. Journal of Investigative Dermatology, 2021, 141, 2151-2160.	0.3	22
160	Reliability and Validity of Cutaneous Sarcoidosis Outcome Instruments Among Dermatologists, Pulmonologists, and Rheumatologists. JAMA Dermatology, 2015, 151, 1317.	2.0	21
161	<p></p>A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach</p>. Journal of Multidisciplinary Healthcare, 2019, Volume 12, 419-428.	1.1	21
162	Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. British Journal of Dermatology, 2020, 182, 949-954.	1.4	21

#	ARTICLE	IF	CITATIONS
163	Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis. <i>Theranostics</i> , 2021, 11, 7144-7158.	4.6	21
164	Cutaneous Lupus Erythematosus Patients With a Negative Antinuclear Antibody Meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 1404-1409.	1.5	20
165	Development of outcome measures for autoimmune dermatoses. <i>Archives of Dermatological Research</i> , 2008, 300, 3-9.	1.1	19
166	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. <i>Neuromuscular Disorders</i> , 2016, 26, 523-534.	0.3	19
167	The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (<scp>CDASI</scp>) among dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , 2017, 176, 423-430.	1.4	19
168	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. <i>Arthritis and Rheumatology</i> , 2021, 73, 2151-2160.	2.9	19
169	Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire. <i>Lupus Science and Medicine</i> , 2015, 2, e000085-e000085.	1.1	18
170	Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis. <i>British Journal of Dermatology</i> , 2017, 176, 231-233.	1.4	18
171	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus "An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 270-276.	0.3	18
172	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2020, 156, 901.	2.0	18
173	Decreased secretion of adiponectin through its intracellular accumulation in adipose tissue during tobacco smoke exposure. <i>Nutrition and Metabolism</i> , 2015, 12, 15.	1.3	17
174	Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. <i>British Journal of Dermatology</i> , 2018, 178, 1308-1314.	1.4	17
175	The effects of immunostimulatory herbal supplements on autoimmune skin diseases. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1051-1058.	0.6	17
176	Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1562-1567.	0.6	17
177	Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2651-2659.e1.	0.3	17
178	Dermatologic therapeutics: thalidomide. A practical guide. <i>Dermatologic Therapy</i> , 2007, 20, 175-186.	0.8	16
179	Rheumatic manifestations of skin disease. <i>Current Opinion in Rheumatology</i> , 2010, 22, 78-84.	2.0	16
180	Update on pathogenesis and treatment of CLE. <i>Current Opinion in Rheumatology</i> , 2013, 25, 584-590.	2.0	16

#	ARTICLE	IF	CITATIONS
181	Treatment of cutaneous lupus erythematosus: current practice variations. <i>Lupus</i> , 2016, 25, 964-972.	0.8	16
182	Malignancy in dermatomyositis: A retrospective study of 201 patients seen at the University of Pennsylvania. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 117-122.	0.6	16
183	Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. <i>F1000Research</i> , 2019, 8, 332.	0.8	16
184	Ultraviolet-B Recruits Mannose-Binding Lectin into Skin from Non-Cutaneous Sources 11 Portions of this work were presented at the 2003 Annual Scientific Sessions of the Society for Investigative Dermatology and published in abstract form: Mannose binding lectin in UV-irradiated skin. <i>J Invest Dermatol</i> 121:77, 2003 (abstr)... <i>Journal of Investigative Dermatology</i> , 2005, 125, 166-173.	0.3	15
185	Quality of Life and Disease Severity in a Cutaneous Lupus Erythematosus Pilot Study. <i>Archives of Dermatology</i> , 2008, 144, 1061-2.	1.7	15
186	Dapsone in the Management of Autoimmune Bullous Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 317-322.	0.7	15
187	Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. <i>JAAD Case Reports</i> , 2018, 4, 698-700.	0.4	15
188	Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists. <i>British Journal of Dermatology</i> , 2019, 180, 165-171.	1.4	15
189	Effect of TNF α blockade on UVB-induced inflammatory cell migration and collagen loss in mice. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2020, 213, 112072.	1.7	15
190	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 431-431.	0.7	15
191	Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid. <i>Archives of Dermatological Research</i> , 1998, 290, 388-393.	1.1	14
192	PRESERVING MEDICAL DERMATOLOGY. <i>Dermatologic Clinics</i> , 2001, 19, 583-592.	1.0	14
193	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , 2014, 66, S70-S71.	2.9	14
194	Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1109-1121.	1.3	14
195	Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 464-469.e2.	0.6	14
196	An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice. <i>Current Rheumatology Reports</i> , 2020, 22, 69.	2.1	14
197	Incidence of alopecia areata in lupus erythematosus. <i>Archives of Dermatology</i> , 1992, 128, 368-71.	1.7	14
198	The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 374-377.	0.6	13

#	ARTICLE	IF	CITATIONS
199	Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus. <i>Frontiers in Immunology</i> , 2019, 10, 2571.	2.2	13
200	Bullous pemphigoid in adolescence. <i>Pediatric Dermatology</i> , 2019, 36, 184-188.	0.5	13
201	Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
202	Treatment of Discoid Skin Lesions With Azathioprine. <i>Archives of Dermatology</i> , 1986, 122, 746.	1.7	12
203	Glucocorticoids in the treatment of bullous diseases. <i>Dermatologic Therapy</i> , 2002, 15, 298-310.	0.8	12
204	Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1053-1060.e3.	0.6	12
205	Myeloid Dendritic Cells Are Major Producers of IFN- γ in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1906-1914.e2.	0.3	12
206	Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. <i>Lupus Science and Medicine</i> , 2022, 9, e000581.	1.1	12
207	Scoring Systems for Blistering Diseases in Practice. <i>JAMA Dermatology</i> , 2014, 150, 245.	2.0	11
208	Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. <i>BioMed Research International</i> , 2018, 2018, 1-5.	0.9	11
209	Blood plasma versus serum: which is right for sampling circulating membrane microvesicles in human subjects?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e73-e73.	0.5	11
210	Evaluating the effect of prior authorizations in patients with complex dermatologic conditions. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1674-1680.	0.6	11
211	Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: A cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 447-448.	0.6	11
212	Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2016-218786.	0.2	11
213	Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. <i>Archives of Dermatology</i> , 1996, 132, 1435-9.	1.7	11
214	Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea. <i>Dermatologic Clinics</i> , 2016, 34, 243-250.	1.0	10
215	The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 42-48.	0.6	10
216	Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis. <i>British Journal of Dermatology</i> , 2017, 176, 853-854.	1.4	10

#	ARTICLE	IF	CITATIONS
217	Acute onset/flare of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 801-804.	0.6	10
218	Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1777-1785.	2.9	10
219	The Proper Future for Medical Dermatology. <i>Archives of Dermatology</i> , 1998, 134, 1159-b-1160.	1.7	10
220	Rho Kinase regulates neutrophil NET formation that is involved in UVB-induced skin inflammation. <i>Theranostics</i> , 2022, 12, 2133-2149.	4.6	10
221	Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials. <i>Arthritis and Rheumatology</i> , 2022, 74, 1687-1698.	2.9	10
222	A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 180, 964-965.	1.4	9
223	The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 458-462.	1.6	9
224	Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum™. <i>Arthritis Research and Therapy</i> , 2022, 24, 12.	1.6	9
225	Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. <i>Lupus Science and Medicine</i> , 2021, 8, e000529.	1.1	9
226	Whither the patient-oriented researcher?. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 109-113.	0.6	8
227	Dermatomyositis Autoantibodies. <i>Archives of Dermatology</i> , 2011, 147, 492.	1.7	8
228	Thalidomide-Induced Orofacial Neuropathy. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 399-400.	0.5	8
229	Cutaneous Lupus Erythematosus: Current Treatment Options. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 36-48.	0.6	8
230	Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice. <i>British Journal of Dermatology</i> , 2019, 181, 1090-1092.	1.4	8
231	Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1793-1794.	0.6	8
232	Practice-based differences in paediatric discoid lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 181, 805-810.	1.4	8
233	Fatigue in systemic lupus erythematosus and other autoimmune skin diseases. <i>British Journal of Dermatology</i> , 2019, 180, 1468-1472.	1.4	8
234	Classifying discoid lupus erythematosus: background, gaps, and difficulties. <i>International Journal of Women's Dermatology</i> , 2016, 2, 8-12.	1.1	7

#	ARTICLE	IF	CITATIONS
235	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000430.	1.1	7
236	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021, 8, e000433.	1.1	7
237	Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study. <i>Lupus</i> , 2021, 30, 096120332110160.	0.8	7
238	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 560-575.	1.1	7
239	Failure of physiologic doses of pure UVA or UVB to induce lesions in photosensitive cutaneous lupus erythematosus: implications for phototesting. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2006, 22, 290-296.	0.7	6
240	Drug-induced dermatomyositis after lacosamide: A case report. <i>JAAD Case Reports</i> , 2018, 4, 584-585.	0.4	6
241	Recent Advances in Pharmacological Treatments of Adult Dermatomyositis. <i>Current Rheumatology Reports</i> , 2019, 21, 53.	2.1	6
242	Geospatial Correlation of Amyopathic Dermatomyositis With Fixed Sources of Airborne Pollution: A Retrospective Cohort Study. <i>Frontiers in Medicine</i> , 2019, 6, 85.	1.2	6
243	Supplementing Dermatology Physician Resident Education in Vasculitis and Autoimmune Connective Tissue Disease: A Prospective Study of an Online Curriculum. <i>JAMA Dermatology</i> , 2019, 155, 381.	2.0	6
244	Drug-induced subacute cutaneous lupus erythematosus in previously diagnosed systemic lupus erythematosus patients: A case series. <i>JAAD Case Reports</i> , 2021, 12, 18-21.	0.4	6
245	Cutaneous lupus concerns from the patient perspective: a qualitative study. <i>Lupus Science and Medicine</i> , 2021, 8, e000444.	1.1	6
246	Sclerotic skin disease development following COVID-19 vaccination. <i>JAAD Case Reports</i> , 2022, 22, 74-77.	0.4	6
247	The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: Comment on the article by Stamm et al. <i>Arthritis and Rheumatism</i> , 2008, 59, 601-602.	6.7	5
248	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. <i>International Journal of Women's Dermatology</i> , 2016, 2, 44-45.	1.1	5
249	Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. <i>Postepy Dermatologii I Alergologii</i> , 2018, 35, 192-198.	0.4	5
250	Evaluating cutaneous lupus disease activity end points and their effects on quality of life as an outcome measure for clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 841-842.	1.4	5
251	Systemic sclerosis: Update for oral health care providers. <i>Special Care in Dentistry</i> , 2020, 40, 418-430.	0.4	5
252	Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials. <i>Lupus</i> , 2022, 31, 472-481.	0.8	5

#	ARTICLE	IF	CITATIONS
253	Emerging Therapies in Cutaneous Lupus Erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
254	Pathogenesis of Cutaneous Lupus Erythematosus: The Role of Ultraviolet Light. , 2005, , 251-266.		4
255	Medical Dermatology: A View to the Future. <i>Journal of Investigative Dermatology</i> , 2006, 126, 528-529.	0.3	4
256	Skin Disease in Cutaneous Lupus Erythematosus. , 2013, , 319-332.		4
257	Iceâ€pack Dermatitis: A Diagnostic Pitfall for Dermatopathologists that Mimics Lupus Erythematosus. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1-4.	0.7	4
258	Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis. <i>British Journal of Dermatology</i> , 2017, 176, 262-264.	1.4	4
259	Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 572-574.	0.6	4
260	Increased <sc>MxA</sc> protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a singleâ€center caseâ€control study. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 364-373.	0.7	4
261	Measurement of disease severity in cutaneous autoimmune diseases. <i>F1000prime Reports</i> , 2013, 5, 19.	5.9	4
262	Osteoporosis in Health and Disease: A Dermatologist's Perspective. <i>Dermatologic Clinics</i> , 2006, 24, 241-249.	1.0	3
263	SAT0255â€..A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus. , 2017, , .		3
264	Importance of recognition and improved treatment for antimelanoma differentiationâ€associated protein 5â€associated dermatomyositis. <i>British Journal of Dermatology</i> , 2017, 177, 1168-1169.	1.4	3
265	605 Study of safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. <i>Journal of Investigative Dermatology</i> , 2018, 138, S103.	0.3	3
266	1004 Increased tissue-resident memory T (TRM) cells and STAT3 expression in cutaneous lupus erythematosus patients refractory to antimalarials. <i>Journal of Investigative Dermatology</i> , 2019, 139, S174.	0.3	3
267	Evaluating results of an interferon-Î³ release assay in patients with autoimmune disease who are taking hydroxychloroquine. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1162-1164.	0.6	3
268	Custom dental trays with topical corticosteroids for management of gingival lesions of mucous membrane pemphigoid. <i>International Journal of Dermatology</i> , 2020, 59, e211-e213.	0.5	3
269	The incidence of bullous pemphigoid continues to increase in England. <i>British Journal of Dermatology</i> , 2021, 184, 5-6.	1.4	3
270	Preliminary definition of flare in cutaneous lupus erythematosus using the Cutaneous Lupus Erythematosus Disease Area and Severity Index. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	3

#	ARTICLE	IF	CITATIONS
271	Frequency of immunostimulatory herbal supplement use among patients with autoimmune skin disease. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1093-1095.	0.6	3
272	Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy. <i>Journal of Investigative Dermatology</i> , 2022, 142, 936-943.	0.3	3
273	Identification of Similarities Between Skin Lesions in Patients With Antisynthetase Syndrome and Skin Lesions in Patients With Dermatomyositis by Highly Multiplexed Imaging Mass Cytometry. <i>Arthritis and Rheumatology</i> , 2022, 74, 882-891.	2.9	3
274	Phase 2 <scp>BELIEVE</scp> study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
275	Glucocorticoids in autoimmune connective tissue diseases. <i>Dermatologic Therapy</i> , 2001, 14, 134-142.	0.8	2
276	Therapy of cutaneous lupus erythematosus. <i>Expert Review of Dermatology</i> , 2006, 1, 105-120.	0.3	2
277	Cutaneous lupus erythematosus flare following exposure to surgical light during a dental procedure. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212864.	0.2	2
278	How Can We Promote Physician-Directed Research in Complex Medical Dermatology?. <i>Journal of Investigative Dermatology</i> , 2016, 136, 885-887.	0.3	2
279	1081 B1IB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE). <i>Journal of Investigative Dermatology</i> , 2018, 138, S183.	0.3	2
280	Relative risk of microscopic colitis in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1188-1190.	0.6	2
281	Launching lollipops? Perforating osteoma cutis in nephrogenic systemic fibrosis. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 467-470.	0.7	2
282	Management of Cutaneous Lupus Erythematosus. , 2019, , 719-726.		2
283	Photosensitivity in Lupus Erythematosus and Dermatomyositis. <i>Current Dermatology Reports</i> , 2020, 9, 93-99.	1.1	2
284	Establishing cutoff values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index. <i>British Journal of Dermatology</i> , 2021, 184, 975-977.	1.4	2
285	Wong's Type Dermatomyositis in an African American Patient. <i>Arthritis and Rheumatology</i> , 2021, 73, 630-630.	2.9	2
286	Diagnosing muscle disease in a cohort of classic dermatomyositis patients seen at a rheumatologic dermatology outpatient clinic. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	2
287	Ultraviolet light exposure from manicures in cutaneous lupus erythematosus. <i>Rheumatology</i> , 2022, 61, e38-e39.	0.9	2
288	Dermatomyositis associated with hyponatremia and anasarca. <i>JAAD Case Reports</i> , 2021, 16, 86-89.	0.4	2

#	ARTICLE	IF	CITATIONS
289	Erythromelalgia associated with dermatomyositis: A case series. <i>JAAD Case Reports</i> , 2021, 16, 37-40.	0.4	2
290	FRIO470...A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. , 2018, , .		2
291	How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey. <i>JID Innovations</i> , 2022, 2, 100129.	1.2	2
292	Evaluating quality of life in dermatomyositis. <i>Expert Review of Dermatology</i> , 2010, 5, 605-609.	0.3	1
293	Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis. <i>Current Dermatology Reports</i> , 2013, 2, 48-57.	1.1	1
294	Bullous Pemphigoid, Mucous Membrane Pemphigoid and Pemphigus Vulgaris: An Update on Pathobiology. <i>Current Oral Health Reports</i> , 2014, 1, 180-189.	0.5	1
295	Effect of long-term treatment with tumour necrosis factor- α inhibitors on single-dose ultraviolet-induced changes in human skin. <i>British Journal of Dermatology</i> , 2017, 177, 1762-1764.	1.4	1
296	83...Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus. , 2017, , .		1
297	Understanding cutaneous lupus erythematosus: a step forward. <i>British Journal of Dermatology</i> , 2019, 180, 1292-1293.	1.4	1
298	Identifying the required degree of disease clearance to improve quality of life in pemphigus vulgaris. <i>British Journal of Dermatology</i> , 2021, 184, 573-575.	1.4	1
299	Response to: "Correspondence on EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups" by Irfan et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e41-e41.	0.5	1
300	A prospective cohort study comparing the performance of interferon gamma release assays in autoimmune skin diseases. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 948-949.	0.6	1
301	Immunological and clinical heterogeneity in cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2021, 185, 480-481.	1.4	1
302	Collaboration for the Management of Hydroxychloroquine. <i>Ophthalmology</i> , 2021, 128, 1115-1116.	2.5	1
303	A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials. <i>JAMA Dermatology</i> , 2021, 157, 1112.	2.0	1
304	THU0241...Ethnic but not gender differences in disease manifestations in dermatomyositis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 236.3-236.	0.5	1
305	10th Annual Meeting of the Rheumatologic Dermatology Society. <i>Annals of Translational Medicine</i> , 2019, 7, S159-S159.	0.7	1
306	Management of autoimmune blistering diseases in pregnancy and the neonate. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 539-549.	0.8	1

#	ARTICLE	IF	CITATIONS
307	Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 583-587.	1.1	1
308	Dermatology vignette. Pseudoporphyria caused by NSAIDs. <i>Journal of Clinical Rheumatology</i> , 2001, 7, 123.	0.5	1
309	Preliminary definition of cutaneous flare in dermatomyositis: A retrospective review. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 190-191.	0.6	1
310	Defining anti-synthetase syndrome: a systematic literature review.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 309-319.	0.4	1
311	Ulcerating Skin Lesions and Arthritis After a Crab Bite. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 181.	0.5	0
312	Cutaneous infections of the head and neck. <i>Facial Plastic Surgery Clinics of North America</i> , 2003, 11, 165-173.	0.9	0
313	OP0035...Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A60.2-A60.	0.5	0
314	Challenges in measuring outcomes: Size assessment of an individual cutaneous lesion. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 402-404.	0.6	0
315	Response letter to "chronic cutaneous lupus erythematosus induced by 5-fluorouracil". <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 919-920.	1.3	0
316	Patient-oriented outcomes for atopic dermatitis. <i>British Journal of Dermatology</i> , 2021, 184, 794-795.	1.4	0
317	Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1157-1160.	0.6	0
318	Why rheumatologic skin disease?. <i>Annals of Translational Medicine</i> , 2021, 9, 428-428.	0.7	0
319	Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e47-e48.	0.6	0
320	Dapsone and Autoimmune Bullous Disorders. , 2015, , 493-499.		0
321	Pemphigoid Gestationis. , 2016, , 149-162.		0
322	Cutaneous Outcome Measures of Adult Dermatomyositis. , 2019, , 1-7.		0
323	Interventions for Cutaneous Disease in Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2022, 158, 200.	2.0	0
324	Emerging therapies for cutaneous lupus erythematosus. <i>Cutis</i> , 2020, 105, 276-277.	0.4	0

#	ARTICLE	IF	CITATIONS
325	Reply. Arthritis and Rheumatology, 2022, 74, 1301-1301.	2.9	0
326	Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis. British Journal of Dermatology, 2022, , .	1.4	0
327	Postinflammatory hyperpigmentation and erythema: new insights into the pathogenesis. British Journal of Dermatology, 2022, 186, 390-391.	1.4	0